Erlotinib: applications in therapy and current status of research. (Q54777001)

3 June 2018

title

Erlotinib: applications in therapy and current status of research. (English)

1 reference

3 June 2018

1 reference

Rachel E Sanborn

1

1 reference

3 June 2018

Angela M Davies

series ordinal

2

1 reference

3 June 2018

language of work or name

English

0 references

publication date

1 January 2009

1 reference

3 June 2018

Expert Review of Clinical Pharmacology

published in

1 reference

3 June 2018

volume

2

1 reference

3 June 2018

issue

1

1 reference

3 June 2018

page(s)

15-36

1 reference

3 June 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

cites work

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Velvet, a dominant Egfr mutation that causes wavy hair and defective eyelid development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor: morphological demonstration of binding, internalization, and lysosomal association in human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Overexpression of EGFR and c‐erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Recurrent responses to non-small cell lung cancer brain metastases with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Response of intracranial metastases to erlotinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Clinical and molecular characteristics of malignant transformation of low-grade glioma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Systemic chemotherapy for advanced bladder cancer: update and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17512433.2.1.15

21 January 2018

Identifiers

DOI

10.1586/17512433.2.1.15

1 reference

3 June 2018

1 reference

3 June 2018